{"id":763721,"date":"2023-06-14T09:52:50","date_gmt":"2023-06-14T13:52:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/"},"modified":"2023-06-14T09:52:50","modified_gmt":"2023-06-14T13:52:50","slug":"precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/","title":{"rendered":"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy"},"content":{"rendered":"<h2>\nUse of HemeScreen\u00ae technology enables diagnosis without the need for painful, invasive sampling<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">NEW HAVEN, Conn., June  14, 2023  (GLOBE NEWSWIRE) &#8212; Specialty cancer diagnostics company\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8Vd45gjERNhJLOGQoLzxsWEC4QN4ik8nO2fn4BAOePTZFAznWc10vXRk6PfmndlnaBRZk2Q0-lWJfo_oCRyQIQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Precipio, Inc.<\/u><\/a> leveraged its proprietary <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KdGd4_obvAnAphMSrtEX-v5z2cnJCK6IBe0w7xPrAjaBvomtvon-svK49sdlY54F55f-eFOpUi2Kkuu-xnLqbAMXBsXf6PHi1pANS-AnqebDRBgq5dwjaq0Vs5awmvTe2iD2lLWo7JpX7BDhRYvPc4i7X2HTd42BEeVlSKTI8VU=\" rel=\"nofollow noopener\" target=\"_blank\">HemeScreen Cytopenia panel<\/a> as part of the diagnostic process for molecular identification of driver mutations in a patient with a history of transfusion-dependent anemia and experiencing progressive weakness and neurological symptoms. The findings point to an underlying myeloid stem cell disorder, including a myelodysplastic syndrome and possibly a higher-grade myeloid neoplasm.<\/p>\n<p align=\"justify\">A major advantage in the case work-up using the Omnia methodology was the ability to detect these driver mutations using only a peripheral blood sample and not requiring a further bone marrow biopsy to confirm pathology suspicions. This enabled a more comprehensive and rapid result for the clinician to act upon to manage patient care.<\/p>\n<p align=\"justify\">In this case, the detection of ASXL1 and WT1 mutations are associated with a poor prognosis, further reinforcing the need for accuracy and speed in this case work-up.<\/p>\n<p align=\"justify\">\u201cProviding a comprehensive diagnosis with minimally invasive sample procurement is critical to informing treatment decisions,\u201d said Ilan Danieli, Precipio CEO. \u201cNot only does this enable our lab to deliver a rapid diagnosis, but greatly improves patient compliance from those who would otherwise need a more invasive, follow up bone marrow biopsy to confirm results.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Precipio<\/strong>\n      <\/p>\n<p align=\"justify\">Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_zSDJ87I0cdpSWgOKQdDjpzYR_BT-_uaf2X9KrDti_iWCkf8H8xjCEQo8CFMAz7ogleBnExWHvu_lqFobXAv6vZkUM34T1nL_Xr4o_NnDMo=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.precipiodx.com<\/u><\/a>.<\/p>\n<p align=\"justify\">Please follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pipQ_gmkf3XUPruFP6xIpV9xSL1kVNajae3OZUQQkagJknGM4WHGxOtxvxxO7R9q3PezbavgybkAbxULiQaHl9C4iSmTHzNptm5wazo3p3Qr7pDFsKfjiQAOngXPbsS7\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a>, Twitter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ASneFKBif_jmDPmfURExDaTtElqTUNv-HQvZXZCvAIQTOTf8SX0zNwQK1-DN08TD3GqfRz3m_zvdoz8L6FI52fbfw0MKf5ny6xiCCJhY25A=\" rel=\"nofollow noopener\" target=\"_blank\"><u>@PrecipioDx<\/u><\/a> and on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OsFfURaFSUyR1M3q6Wf9BhhLxUqTQg17cZ6CD9wMuWpuzm33P4c9daejbvoAQ8BxyaYkNAWc4yMcBvIQPQ_TjQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Facebook<\/u><\/a>.<\/p>\n<p align=\"justify\">Inquiries:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ECVGZemTDED-T0KCCAwXKQoQyRapA6CYGk-0brO8CKmG4bPDP2B6k3R7Lr08TDsVenbS4eubZIl9Ab-fMFGAn4Lu7YlTWcxYiLMWWcSfoUc=\" rel=\"nofollow noopener\" target=\"_blank\">contact@precipiodx.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IUajhPZxXf6r6t4vsc1RMS82foq3ttdmnv2h5xcsKbq3Y87_ackvdR0GLxwCjyiDc0ue1JTy01txGZkof4ln2A==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a>+1-203-787-7888<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/N2E5ZDEyMWItNDRlYS00M2UwLTgzYWUtNmZlOGExN2UxMDcwLTExMDc1ODY=\/tiny\/Precipio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Use of HemeScreen\u00ae technology enables diagnosis without the need for painful, invasive sampling NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) &#8212; Specialty cancer diagnostics company\u00a0Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for molecular identification of driver mutations in a patient with a history of transfusion-dependent anemia and experiencing progressive weakness and neurological symptoms. The findings point to an underlying myeloid stem cell disorder, including a myelodysplastic syndrome and possibly a higher-grade myeloid neoplasm. A major advantage in the case work-up using the Omnia methodology was the ability to detect these driver mutations using only a peripheral blood sample and not requiring a further bone marrow biopsy to confirm pathology suspicions. This enabled &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-763721","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Use of HemeScreen\u00ae technology enables diagnosis without the need for painful, invasive sampling NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) &#8212; Specialty cancer diagnostics company\u00a0Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for molecular identification of driver mutations in a patient with a history of transfusion-dependent anemia and experiencing progressive weakness and neurological symptoms. The findings point to an underlying myeloid stem cell disorder, including a myelodysplastic syndrome and possibly a higher-grade myeloid neoplasm. A major advantage in the case work-up using the Omnia methodology was the ability to detect these driver mutations using only a peripheral blood sample and not requiring a further bone marrow biopsy to confirm pathology suspicions. This enabled &hellip; Continue reading &quot;Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-14T13:52:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy\",\"datePublished\":\"2023-06-14T13:52:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/\"},\"wordCount\":332,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/\",\"name\":\"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=\",\"datePublished\":\"2023-06-14T13:52:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/","og_locale":"en_US","og_type":"article","og_title":"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy - Market Newsdesk","og_description":"Use of HemeScreen\u00ae technology enables diagnosis without the need for painful, invasive sampling NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) &#8212; Specialty cancer diagnostics company\u00a0Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for molecular identification of driver mutations in a patient with a history of transfusion-dependent anemia and experiencing progressive weakness and neurological symptoms. The findings point to an underlying myeloid stem cell disorder, including a myelodysplastic syndrome and possibly a higher-grade myeloid neoplasm. A major advantage in the case work-up using the Omnia methodology was the ability to detect these driver mutations using only a peripheral blood sample and not requiring a further bone marrow biopsy to confirm pathology suspicions. This enabled &hellip; Continue reading \"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-14T13:52:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy","datePublished":"2023-06-14T13:52:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/"},"wordCount":332,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/","name":"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=","datePublished":"2023-06-14T13:52:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1ODI4NyM1NjQ3NTAxIzIwOTYwMTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipios-omnia-methodology-enables-diagnosis-of-mds-with-peripheral-blood-instead-of-bone-marrow-biopsy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Precipio\u2019s Omnia\u2122 Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/763721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=763721"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/763721\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=763721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=763721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=763721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}